Cleveland Clinic notes there's little research and no official guidance on low-dose semaglutide, while trials show far smaller weight loss than standard dosing.
Recap by typeshit. Full story at greatergood.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
Pothier says social media and telehealth pulled GLP-1s partly out of doctors' hands, pushing Novo and Lilly to rethink launches. Novo CEO Mike Doustdar weighs in too.
Novo pays $300 million upfront for HRS-1596, and the OCTANE trial reports 4.1% average weight loss after patients switched from injections to oral semaglutide.
Loading…